We examined 741 urinary tract isolates of the Morganella-Proteus-Providencia group, including the recently defined species Proteus penneri, for susceptibilities to aminoglycosides, semisynthetic penicillins, and cephalosporins. The data emphasize the importance of identification to the species level on the basis of marked species differences in patterns of susceptibility.During the last few years, an increase in the frequency of antibiotic resistance among the Proteeae has been noted (4, 11). Therefore, continued concern about antimicrobial resistance is warranted, as are studies on the activities of new agents. Unfortunately, in studies of in vitro susceptibility, species of Proteeae are often divided into Proteus mirabilis, indole-positive Proteus spp., and Providencia spp. It has been shown that such broad groupings conceal major differences among species in susceptibilities to antimicrobial agents (11).For these reasons, we decided to perform a study of the in vitro susceptibilities of recently and precisely identified isolates of the Morganella-Proteus-Providencia group, including the recently defined species Proteus penneri (3, 5, 6, 9), by standardized susceptibility testing methods performed in our laboratory.A comparison was made between the in vitro activities of amikacin, tobramycin, carbenicillin, azlocillin, piperacillin, temocillin, cefazolin, cefoxitin, and cefuroxime and four newly developed preparations: aztreonam, imipenem, ceftazidime, and ceftriaxone.Laboratory-grade, antibiotic-standard powders were obtained from the manufacturers as follows: azlocillin, Bayer AG, Leverkusen-Bayer Italia, Milan, Italy; ampicillin, carbenicillin, and temocillin,